脑动静脉畸形立体定向放射外科后放射性颅内肿瘤的多中心回顾性队列研究
该多中心回顾性研究纳入日本18家伽玛刀中心1990至2019年因脑动静脉畸形接受立体定向放射外科治疗的患者4376例,中位影像随访100个月,新发颅内肿瘤12例(0.27%),其中野内恶性肿瘤5例(0.11%)、野外肿瘤7例(0.16%)。结论认为放射性恶性肿瘤发生率极低但可能致命,年轻患者需警惕迟发肿瘤并长期监测。
要点
- 脑动静脉畸形SRS后新发颅内肿瘤总体风险约0.27%,野内恶性肿瘤约0.11%。
- 野内恶性肿瘤中位潜伏期13.3年,野外肿瘤17.4年,需长期影像随访。
- 5年后年发病率高于5年内,提示迟发风险随时间累积。
核心结论
- 脑动静脉畸形SRS后放射性恶性肿瘤发生率极低但可能致命,当前风险相对显微外科切除死亡率可接受。
- 年轻患者迟发恶性肿瘤风险值得警惕,随治疗例数和随访延长该风险可能增加,长期监测必不可少。
研究设计与样本
- 多中心回顾性队列研究,分析日本18家伽玛刀中心1990至2019年因bAVM接受SRS的4376例患者匿名数据。
- 排除影像随访不足3年、既往放疗或遗传性肿瘤易感患者,按随访总人年计算年发病率。
主要发现
- 中位影像随访100个月,新发颅内肿瘤12例(0.27%):野内恶性肿瘤5例(0.11%),野外肿瘤7例(0.16%,恶性3例、良性4例)。
- 野内肿瘤10、15、20年累积发生率分别为0.08%、0.16%、0.16%;野外分别为0.11%、0.11%、0.58%。
- 恶性肿瘤10、15、20年累积发生率分别为0.15%、0.24%、0.40%,非恶性肿瘤分别为0.03%、0.03%、0.34%。
- 共43950.3人年影像随访,总体年发病率0.027%,5年内0.005%、5年后0.046%。
- 野内肿瘤年发病率0.011%(5年内0%、5年后0.021%),野外0.016%(5年内0.005%、5年后0.025%)。
临床怎么用
- 脑动静脉畸形SRS后应坚持长期影像随访,尤其关注5年后迟发肿瘤风险。
- 对年轻患者及长期生存者,需在随访中警惕野内和野外新发肿瘤。
局限性
- 为回顾性多中心研究,可能存在随访与报告偏倚。
- 原文未报告各中心SRS具体剂量方案及影像随访方法差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Stereotactic radiosurgery (SRS) is a well-established treatment for brain arteriovenous malformations (bAVMs). However, data on radiation-induced neoplasms (RINs) following SRS in patients with bAVMs remain limited. In this study, authors aimed to evaluate the incidence of newly developed intracranial RINs following SRS for bAVMs. METHODS: The authors retrospectively analyzed anonymized data for patients who underwent SRS for bAVMs between 1990 and 2019 at 18 Gamma Knife centers in Japan. Patients with fewer than 3 years of radiological follow-up, prior radiotherapy, or genetic tumor predisposition were excluded. Newly developed tumors were classified as in field (within the 2-Gy isodose line) or out of field. Annual incidence rates were calculated based on total patient-years of follow-up. RESULTS: During a median radiological follow-up of 100 months, new intracranial tumors developed in 12 (0.27%) of the 4376 patients included in the study. In-field malignant tumors occurred in 5 patients (0.11%), with a median latency of 13.3 years. Out-of-field tumors were observed in 7 patients (0.16%), including malignant (n = 3) and benign (n = 4) neoplasms, with a median latency of 17.4 years. The cumulative incidence of in-field tumors at 10, 15, and 20 years was 0.08%, 0.16%, and 0.16%, respectively. The corresponding incidence of out-of-field tumors was 0.11%, 0.11%, and 0.58%, respectively. In terms of tumor histology, the cumulative incidence of new intracranial brain tumors at 10, 15, and 20 years was 0.15%, 0.24%, and 0.40% for malignant tumors and 0.03%, 0.03%, and 0.34% for nonmalignant tumors, respectively. Across 43,950.3 patient-years of radiological follow-up, the overall annual incidence was 0.027%, increasing from 0.005% within 5 years to 0.046% after 5 years. The annual incidence of in-field tumors was 0.011% (0% within and 0.021% after 5 years) and 0.016% for out-of-field tumors (0.005% within and 0.025% after 5 years). Malignant tumors had an annual incidence of 0.018% (0.005% within and 0.030% after 5 years), whereas benign tumors occurred only out of field with an annual incidence of 0.009% (0% within and 0.017% after 5 years). CONCLUSIONS: The incidence of radiation-induced malignancies after SRS for bAVMs is extremely low but potentially fatal. Although the current risk is acceptable compared to the mortality associated with microsurgical resection, the possibility of late-onset malignancies, especially in younger patients, warrants caution. As more patients are treated and follow-up periods become extended, this risk may increase. Therefore, long-term surveillance is essential for accurately assessing and managing the potential for RINs over time.
引用
- Hasegawa T, Kato T, Umekawa M, et al. Radiation-induced intracranial neoplasms after stereotactic radiosurgery for brain arteriovenous malformations: a retrospective multicenter cohort study. J Neurosurg. 2026. PMID: 41616302. doi:10.3171/2025.9.JNS251807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。